GABARAPL2 and Parkinson disease: Therefore, the significant upregulation of ATG3, ATG7, and GABARAPL2 (1.55‐fold, p = 0.0279; 1.68‐fold, p = 0.0428; and 3.24‐fold, p = 0.0096, respectively) after 6 months of treatment indicates increased autophagy‐inducing functions by sargramostim providing a protective outcome in PD patients.